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Summary
 
Despite overwhelming evidence that enhanced production of the p75 tumor necrosis factor re-
ceptor (p75TNF-R) accompanies development of specific human inflammatory pathologies
such as multi-organ failure during sepsis, inflammatory liver disease, pancreatitis, respiratory
distress syndrome, or AIDS, the function of this receptor remains poorly defined in vivo. We
show here that at levels relevant to human disease, production of the human p75TNF-R in
transgenic mice results in a severe inflammatory syndrome involving mainly the pancreas, liver,
kidney, and lung, and characterized by constitutively increased NF-
 
k
 
B activity in the periph-
eral blood mononuclear cell compartment. This process is shown to evolve independently of
the presence of TNF, lymphotoxin 
 
a
 
, or the p55TNF-R, although coexpression of a human
TNF transgene accelerated pathology. These results establish an independent role for enhanced
p75TNF-R production in the pathogenesis of inflammatory disease and implicate the direct in-
volvement of this receptor in a wide range of human inflammatory pathologies.
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T
 
umor necrosis factor (TNF) is considered to be a po-
tent proinflammatory molecule involved in the patho-
genesis of chronic local or systemic inflammation in vivo
(1). The effects of TNF are signaled via two cell surface re-
ceptors (TNF-R), designated p55 and p75TNF-R, which
are capable of mediating, either in cooperation or indepen-
dently, a wide spectrum of cellular responses ranging from
direct cytotoxicity or apoptosis to cellular proliferation and
differentiation (2, 3). Soluble forms of the two TNF-Rs
(sTNF-R), which represent the extracellular portions of
membrane-associated TNF-Rs and are shed from them by
proteolytic partition, have been identified in serum and
urine (4, 5). Using TNF or TNF-R knockout mice it has
recently been demonstrated that the TNF/p55TNF-R pair
is essential for many physiological processes such as lym-
phoid organ architecture (6, 7), immune cell activation and
trafficking (8), and host defence against bacterial (6, 9, 10)
or viral infections (11). Moreover, a dominant role of the
p55TNF-R is also apparent in several TNF-mediated pa-
thologies, including endotoxemic shock in the presence of
TNF-sensitizing agents (9, 10), or in disease models where
constitutively produced (12–16) or acutely administered
levels of TNF are pathogenic (17). In contrast, using similar
assay systems, there has been very little evidence for a spe-
cific role for the p75TNF-R in delivering TNF-dependent
signals in vivo (2, 18). This may reflect either a well-docu-
mented preference of the p75TNF-R to signal upon bind-
ing to transmembrane (19) rather than soluble TNF (20),
or an apparently essential requirement for this receptor to
reach an induced density state in order to transmit an inde-
pendent biological signal (21, 22). Indeed, a most impor-
tant feature of the p75TNF-R, which distinguishes it from
the p55TNF-R, has been its highly inducible production
mainly on cells of hematopoietic origin (2, 23). Notably,
chronic enhanced production of the soluble p75TNF-R
demarcates many fatal human inflammatory and autoim-
mune conditions, including sepsis (24), chronic viral he-
patic disease (25), acute respiratory distress syndrome (26),
acute pancreatitis (27), lupus (28), rheumatoid arthritis (29),
and AIDS (30). Perhaps most importantly, sustained pro-
duction of the p75TNF-R during disease is rarely accom-
panied by chronically elevated levels of TNF indicating a
regulatory and functional disengagement from TNF (31).
However, an independent role for this receptor in the
pathogenesis of inflammatory disease has never been sug-
gested.
To assess the independent in vivo activities of the
p75TNF-R we have generated and studied transgenic mice
expressing constitutively enhanced, yet disease relevant lev-
els of a wild-type human p75TNF-R. Our studies demon-
strate that this receptor is capable of inducing a severe
multi-organ inflammatory syndrome, affecting mainly the
liver, pancreas, kidney, and lung. Similarly to the pro-
longed NF-
 
k
 
B activation observed in PBMC from human
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septic patients and shown to cause pathology in models of
endotoxemia (32), NF-
 
k
 
B binding activity is found consti-
tutively increased in PBMC from hup75TNF-R transgenic
mice suggesting an in vivo role for the p75TNF-R in trig-
gering this pathogenic cascade. Interestingly, the severity of
pathology developing in the human p75TNF-R transgenic
mice was analogous to the levels of soluble p75TNF-R
measured in the sera of these animals, simulating the quan-
titative correlation between levels of human soluble
p75TNF-R production and severity of human disease (33).
Remarkably, the pathogenic potential of this receptor is
shown here to be exerted even in the absence of its known
ligands, TNF or lymphotoxin 
 
a
 
 (LT
 
a
 
),
 
1
 
 and independently
of the presence of the p55TNF-R. These results establish
an independent role for induced production of the
p75TNF-R in inflammatory disease pathogenesis and sug-
gest that antagonistic intervention with the functioning of
this receptor may potentially be beneficial in a wide range
of associated human pathologies.
 
Materials and Methods
 
Transgenic and Knockout Mice.
 
The hup75TNF-R gene was
isolated from a human genomic P1-bacteriophage library by
PCR screening (Genome Systems Inc., St. Louis, MO) using the
primers 5
 
9
 
-CAT CCC TGG GAA TGC-3
 
9
 
 and 5
 
9
 
-GAA GAG
CGA AGT CGC-3
 
9
 
 that amplify a 214-bp region of hup75TNF-R
cDNA. A SalI-NotI fragment of 
 
z
 
70 kb containing both 5
 
9
 
 and
3
 
9
 
 sequences from the hup75TNF-R cDNA was prepared by
centrifugation on a 5–25% (wt/vol) NaCl gradient and microin-
jected into CBA/C57BL/6J fertilized eggs, as described else-
where (34). To identify transgenic founder mice, DNA was iso-
lated from tail biopsies, digested with Sac I, and hybridized with a
640-bp XhoI-BglII fragment of hup75 cDNA. Transgenic proge-
nies were identified by Southern and slot blot hybridization anal-
ysis. TNF (6), LT
 
a
 
 (35; The Jackson Laboratory, Bar Harbor,
ME), p55TNF-R (9; provided by Dr. Bluethmann, Hoffman-La
Roche, Nutley, NJ), or p75TNF-R (18; provided by Dr. Moore,
Genentech Inc., South San Francisco, CA) knockout mice were
maintained on a mixed 129Sv
 
 3 
 
C57Bl/6 genetic background in
the animal facilities of the Hellenic Pasteur Institute.
 
RNA Preparation and Analysis.
 
Total RNA was extracted
from freshly dissected mouse tissues and S1 nuclease protection
analysis was performed as described previously (36) by hybridizing
25 
 
m
 
g of total RNA to a 3-kb 5
 
9
 
-
 
32
 
P-end–labeled BglII probe de-
rived from the 5
 
9
 
-end of the hup75TNF-R cDNA plus vector se-
quences. Correct initiation of transcription from the hup75TNF-R
gene produces a mRNA that protects 590 nt of the probe from
S1 digestion. Endogenous mouse p75TNF-R expression was
monitored by a 3.7 kb 5
 
9
 
-
 
32
 
P-end–labeled BglII probe derived
from the 5
 
9
 
-end of mup75TNF-R cDNA plus vector sequences
(protected fragment 137 bp). A 5
 
9
 
-end–labeled 
 
b
 
-actin DNA
probe (protected fragment 110 bp) was used to control for quan-
titative differences between RNA preparations.
 
Thymocyte Proliferation Assay.
 
Freshly isolated murine thymo-
cytes from 5-wk-old mice were cultured in 96-well flat-bot-
tomed culture plates (6
 
 3 
 
10
 
5
 
/0.1 ml; Costar Corp., Cambridge,
 
MA) in DMEM medium supplemented with 5% FCS (Globe-
pharm Ltd, Esher, UK), 
 
L
 
-glutamine, penicillin, streptomycin,
nonessential amino acids (GIBCO BRL, Gaithersburg, MD) and
2-mercapto-ethanol (Sigma Chemical Co., La Verpilliere, France)
in the presence of 1 
 
m
 
g/ml Con A (Sigma Chemical Co.). Human
rTNF (specific activity 6
 
 3 
 
10
 
7
 
 U/mg) was provided by the
Genentech manufacturing group (Genentech Inc., South San Fran-
cisco, CA). Con A and human rTNF were added to a final volume
of 0.2 ml. After 60 h at 37
 
8
 
C, cultures were pulsed with 1 
 
m
 
Ci of
[
 
3
 
H]thymidine (25 Ci/mmol, 1 mCi
 
 5 
 
37 MBq; Amersham Life
Science Ltd, Little Chalfont, UK) for 18 h and harvested onto glass
fiber filters (Skatron Instruments, Lier, Norway). [
 
3
 
H]thymidine in-
corporation (cpm) of triplicate cultures was determined using a liq-
uid scintillation counter (LKB Wallac, Turku, Finland).
 
TNF and LPS Administration.
 
Recombinant human TNF
(Genentech Inc.) was administered intravenously at 60–150 
 
m
 
g/
mouse in 0.2 ml of PBS. Susceptibility to LPS was assessed by in-
jecting mice (10–12 wk of age) intraperitoneally with 200–1,200
 
m
 
g/25 g of body weight with LPS (
 
Salmonella enteritis
 
; Sigma
Chemical Co.) in 0.2 ml saline. Control and transgenic mice are
littermates. Lethality was monitored for 5 d and indicated as le-
thality/total injected mice.
 
Flow Cytometry.
 
Freshly isolated murine thymocytes were ad-
justed to 2
 
 3 
 
10
 
6
 
 cells/ml in DMEM (GIBCO BRL) supple-
mented as described above and activated with 1 
 
m
 
g/ml Con-
canavalin A (Sigma Chemical Co.) for 24 h at 37
 
8
 
C. Whole
blood was collected in heparinized tubes followed by erythrocyte
depletion. To determine the expression of murine or human
p75TNF-R on thymocytes or whole blood cells, 10
 
6
 
 cells were
stained with a specific anti-mup75TNF-R antibody (rabbit poly-
clonal biotin-conjugated 1:600, provided by Dr. Wim Buurman,
University of Limburg, The Netherlands) or a specific anti-
hup75TNF-R antibody (M80, rabbit polyclonal 1:500, provided
by Dr. Matthias Grell, University of Stuttgart; reference 37) in
100 
 
m
 
l PBA (0.1% BSA, 0.01% sodium azide in PBS) for 30 min
at 4
 
8
 
C. After two washes with PBS, cells were incubated either
by streptavidine-phycoerythrine (1:1,000; PharMingen, San Di-
ego, CA) to detect mup75TNF-R or phycoerythrine-conjugated
anti-rabbit IgG (1:100; Vector Laboratories, Inc., Burlingame,
CA) to detect hup75TNF-R. Cells were analyzed on a Becton
Dickinson Calibur flow cytometer, using the CellQuest software
(Becton Dickinson & Co., Sparks, MD).
 
ELISA for Murine and Human p75TNF-R.
 
Serum was col-
lected 6 h after intraperitoneally injections of 100 
 
m
 
g LPS (
 
Salmo-
nella enteritis
 
; Sigma Chemical Co.). The ELISA assays for murine
and human p75TNF-Rs were provided by Dr. Wim Buurman
and performed as described earlier (38). In brief, 96-well Im-
muno-Maxisorp Plates (Nunc, Roskilde, Denmark) were coated
overnight at 4
 
8
 
C with polyclonal antibodies specific for either re-
ceptor. Sera and standard titration samples were incubated for 2 h
at room temperature. Subsequently, plates were incubated with
biotin-labeled rabbit polyclonal anti–murine or anti–human
p75TNF-R antibodies, followed by a final incubation with
Horseradish Peroxidase Streptavidin (Vector Laboratories Inc.).
ELISA was developed with 100 
 
m
 
l of 0.5 mg/ml 
 
O
 
-phe-
nyldiamine dihydrochloride (Sigma Chemical Co.) containing
0.03% H
 
2
 
O
 
2
 
, and the reaction was terminated with 50 
 
m
 
l of 2 nM
H
 
2
 
SO
 
4
 
. OD
 
490 
 
was measured using a MRX microplate Reader
(Dynatech, Chantilly, VA).
 
Histopathology and Immunocytochemistry.
 
Tissues from freshly
dissected mice were immersion-fixed overnight in neutral buff-
ered formalin and embedded in paraplast (BDH Laboratory Sup-
plies, Dorset, UK). Sections were cut and stained with hematoxy-
 
1
 
Abbreviations used in this paper:
 
 DAB, diaminobenzidine; DTT, dithio-
threitol; LT
 
a
 
, lymphotoxin 
 
a
 
. 
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lin and eosin according to standard procedures, dehydrated and
mounted in DPX (BDH Laboratory Supplies).
Immunocytochemical analysis was performed on splenic cryo-
stat sections. Immediately before use, sections were fixed for 10
min in acetone containing 0.03% H
 
2
 
O
 
2
 
 to block endogenous
peroxidase activity. For double immunostaining for IgM and
CD3, sections were rehydrated in PBS and incubated with per-
oxidase-labeled goat anti–mouse IgM Ab (Sigma Chemical Co.)
and rat anti–mouse CD3 mAb (clone KT [39] provided by Dr. S.
Cobbold, Sir William Dunn School of Pathology, Oxford, UK)
for 3 h at room temperature. Subsequently, sections were incu-
bated with biotin-conjugated anti-rat IgG antibody (Southern
Biotechnology Associates Inc., Birmingham, AL) followed by
streptavidin-alkaline phosphatase (Vector Laboratories). Bound
peroxidase activity was detected by staining with diaminobenzi-
dine (DAB; Sigma Chemical Co.), and alkaline phosphatase ac-
tivity was visualized with Fast Blue BB Base (Sigma Chemical Co.).
 
Nuclear Extract Preparation and Electrophoretic Mobility Shift As-
says.
 
Blood was collected by cardiac puncture in heparinized
tubes and PBMC were isolated by centrifugation on Histopaque-
1077 gradient (Sigma Chemical Co.) according to the manufac-
turer’s instructions. The mononuclear band was aspirated, washed
with PBS, and analyzed microscopically.
Nuclear proteins were harvested by the method of Dignam
(40). 2
 
 3 
 
10
 
6
 
 PBMC were lysed in 1 vol of cold buffer A (10 mM
Hepes, pH 7.9, 1.5 mM MgCl
 
2
 
, 10 mM KCl, 0.5 mM DTT,
0.5 mM PMSF, 10 
 
m
 
g/ml aprotinin, 10 
 
m
 
g/ml leupeptin, and 10
 
m
 
g/ml type I-S soybean trypsin inhibitor), incubated for 15 min
on ice and centrifuged in an Eppendorf microcentrifuge for 20 s
at highest speed. The pellet was resuspended in 2/3 vol of cold
buffer C (20 mM Hepes, pH 7.9, 420 mM NaCl, 1.5 mM
MgCl
 
2
 
, 0.2 mM EDTA, 25% glycerol, 0.5 mM dithiothreitol
(DTT), 0.5 mM PMSF, 10 
 
m
 
g/ml aprotinin, 10 
 
m
 
g/ml leupep-
tin, and 10 
 
m
 
g/ml type I-S soybean trypsin inhibitor), incubated
on ice for 30 min, and centrifuged for 5 min, 4
 
8
 
C, at highest speed.
The supernatant was quick frozen at 
 
2
 
80
 
8
 
C. Total protein con-
centration was determined according to the Bradford method (41).
Electrophoretic mobility shift assays were performed by incu-
bating 10 
 
m
 
g of nuclear extract with 4 
 
m
 
g of poly (dI-dC; Sigma
Chemical Co.) in a binding buffer (5 nM Hepes, pH 7.9, 5 nM
MgCl
 
2
 
, 50 mM KCl, 0.5 mM DTT, and 10% glycerol), at 20 
 
m
 
l
final volume, for 20 min at RT. An end-labeled, double-stranded,
NF-
 
k
 
B–specific oligonucleotide probe (MWG-Biotech, Ebers-
berg, Germany) containing the two tandemly arranged NF-
 
k
 
B
binding sites of the human immunodeficiency virus long terminal
repeat (5
 
9
 
-ATC AGG GAC TTT CCGCTG GGG ACT TTC
CG-3
 
9
 
) was used to assay for NF-
 
k
 
B binding activity (10),
whereas an end-labeled double-stranded OCT1-specific oligonu-
cleotide probe 5
 
9
 
-TGT CGA ATG CAA ATC ACT AGA A-3
 
9
 
(MWG-Biotech) was used as an internal quantitative control.
Specificity of binding was ascertained by competition with a 150-
fold molar excess of cold consensus NF-
 
k
 
B or OCT1 oligonucle-
otides. Protein–DNA complexes were separated from the free
DNA probe by electrophoresis through 6% native polyacrylamide
gels.
 
Results
 
Transgene Expression Patterns and Protein Production in Hu-
man p75TNF-R Transgenic Mice.
 
The hup75TNF-R gene
was isolated from a human genomic P1-bacteriophage library
by PCR screening (Genome Systems Inc., St. Louis, MO).
 
A large SalI-NotI insert of 
 
z
 
70 kb, was found to contain
both 5
 
9
 
 and 3
 
9
 
 sequences from the hup75TNF-R cDNA
and was used for transgenesis. Three transgenic lines were
generated (TgE1322, TgE1334, and TgE1335) carrying
various transgene copy numbers. The integrity of the in-
serted DNA was confirmed by Southern hybridization
analysis (not shown). To assess whether regulation and tissue
patterns of transgene expression were physiologically rele-
vant, steady state hup75TNF-R mRNA levels were mea-
sured by S1-nuclease protection assays on total RNA from
several transgenic tissues. Correctly initiated hup75TNF-
R-specific transcripts could be detected in several tissues
examined from transgenic mouse lines TgE1334 and
TgE1335 (Fig. 1) or TgE1322 (not shown). Patterns of ex-
pression were comparable to those seen for the endogenous
p75TNF-R mRNA with the highest levels seen in lym-
phoid tissues, liver, and lung (Fig. 1). Overall levels of
transgene expression differed between lines and were de-
pendent on transgene copy number. TgE1334 mice carry-
ing low transgene copy numbers expressed lower levels of
human p75TNF-R compared with the higher transgene
copy number TgE1335 (Fig. 1) or TgE1322 mice (not
shown). These results indicate that important 
 
cis
 
-acting
regulatory elements controlling the expression of the
hup75TNF-R gene were included in the microinjected
fragment and that correctly regulated patterns of transgene
expression could be established in these transgenic mice.
Expression of cell surface p75TNF-Rs was assessed by
flow cytometric analysis on ConA-activated transgenic thy-
mocytes and on freshly isolated peripheral blood cells.
Similar to the expression of murine p75TNF-R on nor-
mal activated thymocytes, induced expression of human
p75TNF-R could be observed on the surface of ConA-
activated transgenic thymocytes (Fig. 2 
 
A
 
), indicating correct
regulation of the hup75TNF-R protein production. More-
over, transgenic PBMC (not shown) or total peripheral
blood leukocytes were also found to express on their sur-
face the human p75TNF-R protein (Fig. 3 
 
B
 
). Further-
more, using double immunostaining of liver sections with
F4/80 and anti-p75TNF-R antibodies, the kupffer cell was
identified as a source of both endogenous or transgenic
p75TNF-Rs (not shown).
Serum levels of soluble human and murine p75TNF-Rs
(sp75TNF-R) were measured in TgE1334 and TgE1335
transgenic mice before or after stimulation by LPS (38).
Both transgenic lines were shown to produce in their se-
rum human sp75TNF-R. TgE1334 mice produced the
transgenic receptor at levels comparable to the endogenous
sp75TNF-R in normal control mice (
 
z
 
10 
 
6 
 
2.5 ng/ml for
either receptor, not shown), whereas TgE1335 mice ex-
pressed an overall three- to fourfold increased levels of
transgenic sp75TNF-R (
 
z
 
33 
 
6 
 
4.3 ng/ml of transgenic
versus 10 
 
6 2.5 ng/ml of the endogenous in normal mice,
Fig. 3 A). After challenge by LPS in vivo, human and mu-
rine sp75TNF-R levels were comparable in heterozygous
TgE1334 (not shown) and TgE1335 mice versus normal
control mice (Fig. 3 A), indicating correct regulation by
LPS of the exogenous p75TNF-R protein production1346 Multi-Organ Inflammation by Increased Expression of the D75TNF-R
and shedding. Interestingly, nonchallenged homozygous
TgE1335 mice produce the transgenic hup75TNF-R pro-
tein at levels similar to those seen for endogenous p75TNF-R
in LPS-treated normal control mice (Fig. 3 A).
The functional integrity of the human p75TNF-R pro-
tein was assessed by measuring its activity in a thymocyte
proliferation assay (42). Transgenic but not normal control
thymocytes were induced to proliferate by exogenous
recombinant human TNF demonstrating the presence of
a functional human p75TNF-R (Fig. 2 B). Taken togeth-
er, these results demonstrate that correctly regulated and
physiologically relevant expression of a functional human
p75TNF-R protein was established in these transgenic
mice.
Enhanced hup75TNF-R Expression Sensitizes Mice to the
In Vivo Toxicity of rhuTNF and LPS. Previous studies in
p75TNF-R knockout mice have indicated an enhancing
role for this receptor in the lethal toxicity of LPS or murine
TNF (18). Additional studies however, have suggested a
neutralizing potential of enhanced levels of soluble TNF-
Rs in models of endotoxemia (38, 43). To assess whether
expression of a human p75TNF-R protein would render
mice more resistant or more susceptible to LPS or huTNF
administration, and to determine the net in vivo effect of
hup75TNF-R overexpression in endotoxemic mice, we
measured lethality rates in Tg1335 and control animals chal-
lenged intravenously or intraperitoneally with different doses
of recombinant huTNF or LPS respectively. Table 1 sum-
marizes the results of these experiments. Human p75TNF-R
expression is shown to potently sensitize transgenic mice
to the toxicity of an otherwise sublethal dose of either
rhuTNF (90 mg) or LPS (800 mg), demonstrating that in-
duced production of the hup75TNF-R protein contributes
positively to the lethal outcome of endotoxemia.
Sustained Overproduction of the p75TNF-R Triggers Multi-
organ Inflammatory Pathology. Mice heterozygous for the
hup75TNF-R transgene from all three transgenic lines
develop and grow normally and display no pathological
changes with the exception of mice from the highest ex-
pressing line TgE1335 that develop a chronic but mild
peri-vascular inflammatory pathology in liver, pancreas,
and lung at 2-3 mo of age (Fig. 4). Notably, homozygous
TgE1335 or TgE1322 mice develop a severe pathology
characterized by runting, lethargy, and abdominal disten-
sion and accompanied by a severely reduced weight gain
(data not shown). The disease leads to the premature death
of these animals between 2 and 4 wk of age. At necropsy of
20-d-old homozygous TgE1335 mice, thymic and pancre-
atic atrophy, splenomegaly, and extensive liver necrosis
were observed. Histopathological analyses revealed heavy
peri-vascular inflammatory lesions in several organs such as
pancreas, liver, lung, and kidney. In addition to heavy in-
flammation, extensive ischemic tissue necrosis could be
observed in the liver (Fig. 4). Other organs and sites such as
muscle and brain meninges were also inflammatory in
homozygous animals. Infiltrates in heterozygous TgE1335
animals consisted mainly of T and B cells, macrophages, and
polymorphonuclear cells as assessed by immunocytochemi-
cal analysis using cell-specific markers (not shown). Interest-
ingly, although a similar infiltrate was present in the heavily
inflamed organs of 2-wk-old homozygous TgE1335 mice, a
striking absence of B220-positive B cells was observed (not
shown). IgM1 B cells were also shown to be markedly de-
creased in sections of spleens from homozygous TgE1335
mice (Fig. 4). FACSÒ-analysis performed in peripheral
blood, spleen, and bone marrow cells of homozygous
TgE1335 mice confirmed the almost complete absence of
B2201IgM2 and B2201IgM1 B cells, indicating impaired
B cell development. In contrast, mature CD41 and CD81
single positive as well as Mac11/Gr11 cells could readily be
detected in both the inflammatory infiltrates and in spleen
and blood of homoTgE1335 mice (not shown).
p75TNF-R-induced Pathology Develops Even in the Absence
of TNF, LTa or the p55TNF-R. To examine the depen-
dency of the observed p75TNF-R–mediated pathology on
the presence of the TNF or LTa ligands, and to evaluate
the contribution of a cooperation of the human p75TNF-R
with the endogenous p75 or p55TNF-Rs, we have intro-
duced the hup75TNF-R transgene, as a homozygous trait,
into genetic backgrounds deficient in either TNF (6), LTa
(35), the p75TNF-R (18), or the p55TNF-R (9). In all
four deficient backgrounds, homozygous TgE1335 mice
developed fully the lethal multi-organ pathology. Increased
levels of the human p75TNF-R are therefore sufficient to
induce disease even in the absence of the p55TNF-R (Fig.
5). Most importantly, the pathogenic potential of the hu-
Figure 1. S1 nuclease protection analysis of total RNA
from tissues of normal, TgE1334 and TgE1335 mice shows
correct patterns of expression for the transgenic p75TNF-R
mRNA. b-actin acts as an internal control for sample loading.1347 Douni and Kollias
man p75TNF-R could be exerted independent of the pres-
ence of TNF (Figs. 4 and 5) or LTa (not shown). Interest-
ingly, however, although the p55TNF-R and LTa were
dispensable for the development of pathology, a low but
measurable pathogenic contribution of the endogenous
TNF could be observed, since in TNF-deficient back-
grounds homozygous TgE1335 mice do succumb to dis-
ease but with a delay of a few weeks (Fig. 5). A measurable
delay in disease progression was also evident in the absence
of the endogenous p75TNF-R (not shown), especially
at the histopathological level where homoTgE1335/
p75TNF-R2/2 mice displayed a generally milder pheno-
type (e.g., fewer inflammatory infiltrates in several organs
and no evidence for necrosis in liver) in comparison to
homoTgE1335 controls, confirming that development of
pathology correlates with the level of p75TNF-Rs being
produced. Consistent with the enhancing pathogenic in-
volvement of endogenous TNF, diseased homozygous
Figure 2. Production of a functional hup75TNF-R protein on the sur-
face of transgenic thymocytes. (A) Freshly isolated or ConA-stimulated
thymocytes from normal, TgE1335, and mup75TNF-R knockout mice
were analyzed by flow cytometry for the expression of murine and human
p75TNF-R protein. Approximately 20 and 22% of freshly isolated nor-
mal and transgenic thymocytes were found to express endogenous or
transgenic p75TNF-R, respectively. ConA stimulation resulted in the in-
duction of both the murine p75TNF-R in normal mice (60% of cells pos-
itive) and the human p75TNF-R in transgenic mice (57% of cells posi-
tive). Thymocytes from normal or p75TNF-R–deficient mice are used as
negative controls. (B) Proliferative response of ConA-treated TgE1335
(d) and normal (s) thymocytes to human rTNF reveals a functional hu-
man p75TNF-R protein. The amount of 3H incorporation in either nor-
mal or transgenic thymocytes treated with ConA alone is indicated by a
dashed line. Results are representative of three independent experiments.
Figure 3. Production of soluble and cell surface hup75TNF-R protein
in transgenic sera and on peripheral blood leukocytes. (A) Serum levels of
soluble mup75 and hup75TNF-Rs were measured by specific ELISAs,
before or after LPS-administration in normal (n 5 4), and TgE1335 het-
erozygous (n 5 4) mice. Total (murine and human) sp75TNF-R produc-
tion in heterozygous TgE1335 mice is increased approximately fivefold in
comparison to the production of endogenous sp75TNF-R protein in
normal mice (49 6 4.5 ng/ml total p75TNF-R protein in transgenic
mice versus 10 6 2.5 ng/ml of endogenous p75TNF-R protein in nor-
mal mice). Transgenic p75TNF-R production in LPS-treated TgE1335
mice is regulated similarly to normal LPS-treated mice. TgE1335 ho-
mozygous mice (n 5 4) spontaneously produce highly elevated levels of
both soluble murine and human p75TNF-Rs. (B) Flow cytometric analy-
sis of peripheral blood leukocytes from 3-wk-old TgE1335 heterozygous
or homozygous mice shows the enhanced surface expression of
hup75TNF-R on leukocytes taken from homozygous transgenic animals.
Data are representative of three independent experiments.1348 Multi-Organ Inflammation by Increased Expression of the D75TNF-R
TgE1335 mice show dramatically increased levels of en-
dogenous TNF in their sera (1.09 ng/ml 6 0.15, n 5 4).
Notably, a similar lethal multi-organ inflammatory disease
could be triggered at 4–8 wk of age, even in the absence of
the p55TNF-R (i.e., in a p55TNF-R knockout back-
ground), in heterozygous TgE1335 mice bred with otherwise
healthy transgenic mice overexpressing T cell targeted human
wild-type (Tg7; reference 15), or transmembrane TNF
(Tg5453; reference 16; not shown). This result shows that in
this model, the pathogenic contribution of TNF results from
direct interaction with the p75TNF-R and does not necessi-
tate a functional p55TNF-R. The lethal phenotype of the
Tg7/TgE1335 double heterozygotes, but not the baseline in-
flammatory complications of the heterozygous TgE1335 line
could be completely neutralized by preventive treatment of
mice with a specific anti-human TNF antibody (CB0006;
Celltech Therapeutics Ltd, Slough, UK; not shown). These
results demonstrate that, in vivo, the p75TNF-R mediates
inflammatory signals independently of the presence or coacti-
vation of the p55TNF-R. Moreover, although the presence
of TNF could further enhance the spontaneous inflammatory
activities of the p75TNF-R, its role in the activation of these
deleterious functions was nonessential.
Enhanced NF-kB Binding Activity in Nuclear Extracts of
PBMC from hup75TNF-R Transgenic Mice. NF-kB activa-
tion is believed to be important in the triggering of proin-
flammatory cytokine cascades (44) and it has recently been
Figure 4. p75TNF-R-trig-
gered multi-organ inflammation
and hematopoietic abnormalities
develop even in the absence of
TNF. Histopathological analysis
(H/E) in liver and pancreas of
4-mo-old heterozygous TgE1335
mice (TgE1335het) and 3-wk-
old TgE1335 homozygous
(TgE1335hom) or homozygous
TgE1335 3 TNF2/2 mice
(TgE1335hom/TNF2/2). Le-
sions in heterozygous Tg1335
mice involve mainly the liver
and pancreas where inflamma-
tory infiltrates develop and per-
sist chronically from 2–3 mo of
age. In homozygous TgE1335
mice a more severe pathology
develops, characterized by ex-
tensive periportal inflammation
and tissue necrosis (asterisk) in the
liver, and in a severely hypoplas-
tic and inflamed pancreas. A sim-
ilar histopathology evolves in
homozygous TgE1335 trans-
genic mice bred into a null TNF
background. Original magnifica-
tion 3108. Spleen sections from
homozygous TgE1335 mice are
characterized by markedly re-
duced numbers of IgM1 B cells
(brown) whereas CD31 T cell lo-
calization (blue) seems unaf-
fected. A similar phenotype oc-
curs even in the absence of
endogenous TNF. Original
magnification 3114.
Table 1. Human p75TNF-R Transgenic Mice Are More 
Susceptible to Lethality After Administration of Human rTNF or LPS
Dose Lethality
huTNF (mg/mouse) LPS (mg/25 g) Control TgE1335
60 – 0/3 1/3
90 – 1/6 6/6
150 – 3/3 3/3
– 200 0/7 1/7
– 400 0/7 2/7
– 800 2/7 7/7
– 1200 5/5 5/51349 Douni and Kollias
shown that in vivo NF-kB activation in PBMC plays an
important role in the lethality accompanying LPS-induced
endotoxemia in mice (32). On the other hand, signaling
through the p75TNF-R is known to involve NF-kB acti-
vating pathways (45). Therefore, it was important to assess
the activation status of the NF-kB system in the p75TNF-R
transgenic mice. NF-kB binding activity was determined
by EMSA in nuclear extracts of PBMC from heterozygous
TgE1335 mice at different developmental points. NF-kB
binding activity was found consistently elevated in PBMC
from transgenic versus control mice (Fig. 6), either before
(1 mo of age), during (2 mo), or after (6 mo) development
of pathology, as assessed by simultaneous histopathological
analysis of all experimental mice (not shown). These results
suggest that a possible target pathway of sustained p75TNF-R
activation in PBMC is the NF-kB pathway and offer a
mechanistic link to explain the observed in vivo inflamma-
tory activities of this receptor.
Discussion
Circulating levels of soluble TNF-Rs are constantly
elevated in a variety of clinical conditions including malig-
nant (46), infectious, and sub-acute or chronic inflamma-
tory or autoimmune diseases (33, 47). In several of these
conditions, measurement of sTNF-Rs, especially of the
sp75TNF-R, correlates even better than classical disease-
specific markers to the prognosis, symptoms, and clinical
outcome of the disease (33). For example, sTNF-R levels
have a strong and early prognostic value for disease pro-
gression in HIV-infected patients (30) and in several in-
flammatory diseases such as chronic hepatitis virus infec-
tions (25), acute pancreatitis (27), acute respiratory distress
syndrome (26), SLE (28), and rheumatoid arthritis (29).
The actual involvement of soluble TNF receptors in dis-
ease pathogenesis remains controversial and it has been sug-
gested that they may act both as antagonists of TNF action
by competing with its cell surface receptors, but also as ag-
onists by protecting TNF from degradation and therefore
stabilizing and enhancing its activity (47). Shedding of both
TNF receptors occurs in both a constitutive and inducible
manner, after appropriate stimulation by a plethora of im-
mune activating signals, and in addition to providing the
soluble receptors it is thought to serve in rendering cells
temporarily unresponsive to TNF (47). However, a corre-
lation of induced sTNF-R levels with enhanced expression
of their cell surface precursors in specific cell types remains
possible, especially in the case of the p75TNF-R, the ex-
pression of which is known to be highly inducible by the
same signals that mediate its induced shedding (38, 47). In-
deed, as shown clearly in this study, sustained upregulation
of human p75TNF-R production in transgenic mice, leads
to both an upregulated level of shed soluble receptors but
also to a chronic accumulation of the receptor on the cell
surface. Therefore, it is possible that increased levels of shed
p75TNF-Rs, as seen in human diseases, reflect a similar
upregulation of the cell surface form of the receptor, which
may interfere with immune homeostasis and/or pathogenesis.
Notably, the severity of the inflammatory phenotypes
developing in transgenic lines expressing hup75TNF-R
transgenes correlates positively with the levels of soluble
human p75TNF-R measured in diseased sera. For exam-
ple, heterozygous TgE1334 mice constitutively expressing
only double the physiological levels of p75TNF-Rs do
not show any signs of pathology, whereas heterozygous
TgE1335 mice producing four- to fivefold higher levels
develop a chronic inflammatory disease. On the other
hand, homozygous TgE1335 mice developing a most se-
vere multi-organ inflammatory phenotype are found to
constitutively produce twofold increased levels of total
sp75TNF-Rs in comparison to the levels measured for en-
dogenous p75TNF-Rs in sera from endotoxemic (LPS-
treated) mice (Fig. 3 A). Interestingly, serum sp75TNF-R
levels measured in several human inflammatory diseases, in-
cluding AIDS, are usually two- to fourfold increased over
normal individuals (25–30), whereas even higher levels
have been recorded in septic shock patients (24). Taken to-
gether, our results show that at levels similar to those seen
in human disease, chronic induced production of the
p75TNF receptor in vivo, has detrimental effects to physi-
Figure 5. Survival of hup75TNF-R transgenic mice in the absence of
TNF or the p55TNF-R. All TgE1335 heterozygous mice (Tghet, n 5 10,
s) survive usually past 10 mo of age whereas TgE1335 homozygous mice
(Tghom, n 5 10, d) succumb to the disease during their first month of age
even in the absence of the p55TNF-R (Tghom/p552/2, n 5 6, n). The
presence of TNF contributes positively but is not essential for the devel-
opment of the lethal pathology (Tghom/TNF2/2, n 5 10, j). Survival is
measured as a percentage of the initial number of animals in each geno-
type group.
Figure 6. Enhanced NF-kB
binding activity in PBMC from
hup75 transgenic mice. EMSA
of nuclear extracts from PBMC
isolated from heterozygous
TgE1335 mice or normal con-
trol littermates (n 5 5 per group)
at 1, 2, and 6 mo of age. Specific
NF-kB complexes are indicated
by arrows, whereas OCT-1 probe acts as an internal control for sample
loading. Cold NF-kB or OCT-1 probe was used to indicate specific
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ological homeostasis and leads to a multi-organ inflamma-
tory syndrome in mice. Furthermore, they demonstrate
that the severity of the in vivo proinflammatory activities of
the p75TNF-R correlate positively with its chronic level of
production.
Although our current knowledge of the involvement of
the TNF/p55TNF-R pair in disease pathogenesis is quite
advanced, understanding of the in vivo function of the
p75TNF-R remains vague. Recent studies in p75TNF-R
knockout mice have failed to show a specific function for
this receptor in physiology or in experimental models of
TNF-mediated disease (18, 48) with the exception of its
profound involvement in the cerebral complications of ex-
perimental malaria (49) or in the allergen-induced migra-
tion of Langerhans cells (50). Moreover, in view of the al-
most uniquely known in vitro activities of this receptor on
thymocyte/T lymphocyte proliferation (42), or in the acti-
vation induced apoptosis of CD81 T cells (51), it was quite
surprising that thymocytes and lymphocytes in p75TNF-R
knockout mice were normal (18). The failure to demon-
strate an in vivo independent activity of the p75TNF-R in
the knockout system, together with ample evidence for a
partial agonistic role of this receptor in TNF/p55TNF-
R–mediated responses (14, 52, 53) has led to the hypothesis
that the p75TNF-R serves an accessory role in enhancing
p55TNF-R–mediated signaling. Interestingly, in all cases
where p75TNF-R–specific signaling has been observed, a
high density of this receptor on the cell surface was re-
quired, suggesting that inducibility of this receptor is a pre-
requisite for function (21, 22). Activation of receptors
through induced aggregation is a widespread phenomenon
in cytokine and growth factor signaling (54, 55). Ligand-
induced clustering of receptors seems to be a primary con-
trol mechanism, in particular for constitutively produced
receptors, such as the p55TNF-R. On the other hand,
there is substantial evidence in vitro, that induced produc-
tion of such members of the TNF-R family as the p75 (45,
56) or the p55TNF-R (57), Fas (57), CD40 (45, 58), or
p75NGF-R (59) and the tyrosine kinase receptors for
growth factors (60) may lead to spontaneous signaling even
in the absence of ligand. Our present data are in support of
a physiologically significant role for ligand-independent
signaling in vivo, especially for the p75TNF-R which is
known to be highly induced in pathological conditions.
However, it remains possible that yet unidentified ligands
may contribute to its observed activation.
Our evidence that sustained p75TNF-R overproduction
in mice may lead to inflammatory complications involving
several vital tissues and organs, has important implications
for inflammatory disease pathogenesis in humans. Interest-
ingly, in a recent study addressing kinetics of production of
soluble TNF-R after leakage of high doses of TNF in the
circulation of patients undergoing isolated limb perfusion
therapy (31), it has been observed that levels of soluble
p75TNF-R remain high, long after TNF disappears from
the circulation, suggesting a TNF-independent regulation
of the production and perhaps function of this receptor.
The surprising finding in this study, that the inflammatory
activities of the p75TNF-R occur even in the absence of
TNF, offers a novel mechanism for p75TNF-R function-
ing which may be of pivotal importance in many clinical
conditions including sepsis. It is important to note that al-
though the TNF/p55TNF-R system seems to operate only
in an initial narrow window of time during clinical sepsis
(61), sp75TNF-R levels are found constantly elevated, cor-
relate positively with sepsis scores and show maximal values
in patients that do not survive (24). After the disappointing
neutral outcome of anti-TNF trials in sepsis, and taking
into account the adverse effects of enhanced p75TNF-R
production as presented in this study, it is tempting to spec-
ulate that specific antagonism of this receptor may be bene-
ficial even at late phases of severe sepsis, but also during the
course of many other human inflammatory pathologies
where a positive correlation between soluble p75TNF-R
and disease progression has been observed. The human
p75TNF-R expressing transgenic lines presented in this
study should offer a useful model system to develop and
test the in vivo efficacy of such p75TNF-R antagonistic
substances.
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